These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 22503309)
1. The Canadian Transfusion Surveillance System: what is it and how can the data be used? Ditomasso J; Liu Y; Heddle NM Transfus Apher Sci; 2012 Jun; 46(3):329-35. PubMed ID: 22503309 [TBL] [Abstract][Full Text] [Related]
2. The Quebec hemovigilance system: description and results from the first two years. Robillard P; Nawej KI; Jochem K Transfus Apher Sci; 2004 Oct; 31(2):111-22. PubMed ID: 15501415 [TBL] [Abstract][Full Text] [Related]
3. Risks associated with transfusion of cellular blood components in Canada. Kleinman S; Chan P; Robillard P Transfus Med Rev; 2003 Apr; 17(2):120-62. PubMed ID: 12733105 [TBL] [Abstract][Full Text] [Related]
9. Transfusion reaction reporting in the era of hemovigilance: where form meets function. Dunbar NM; Walsh SJ; Maynard KJ; Szczepiorkowski ZM Transfusion; 2011 Dec; 51(12):2583-7. PubMed ID: 21745209 [TBL] [Abstract][Full Text] [Related]
10. Online reporting system for transfusion-related adverse events to enhance recipient haemovigilance in Japan: a pilot study. Odaka C; Kato H; Otsubo H; Takamoto S; Okada Y; Taneichi M; Okuma K; Sagawa K; Hoshi Y; Tasaki T; Fujii Y; Yonemura Y; Iwao N; Tanaka A; Okazaki H; Momose SY; Kitazawa J; Mori H; Matsushita A; Nomura H; Yasoshima H; Ohkusa Y; Yamaguchi K; Hamaguchi I Transfus Apher Sci; 2013 Feb; 48(1):95-102. PubMed ID: 22954634 [TBL] [Abstract][Full Text] [Related]
11. Hemovigilance in developing countries. Ayob Y Biologicals; 2010 Jan; 38(1):91-6. PubMed ID: 20133151 [TBL] [Abstract][Full Text] [Related]
12. [Blood transfusion safety in a limited resources setting: the elaboration of a rational National Blood Policy in Togo]. Sodahlon YK; Segbena AY; Prince-David M; Gbo KA; Fargier MP; North ML; Malvy DJ Sante; 2004; 14(2):115-20. PubMed ID: 15454371 [TBL] [Abstract][Full Text] [Related]
14. Risks of transfusion. Squires JE South Med J; 2011 Nov; 104(11):762-9. PubMed ID: 22024787 [TBL] [Abstract][Full Text] [Related]
15. [Implementation of hemovigilance in Sub-Saharan Africa]. Dahourou H; Tapko JB; Nébié Y; Kiénou K; Sanou M; Diallo M; Barro L; Murphy E; Lefrère JJ Transfus Clin Biol; 2012 Feb; 19(1):39-45. PubMed ID: 22296906 [TBL] [Abstract][Full Text] [Related]
16. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Cazenave JP; Waller C; Kientz D; Mendel I; Lin L; Jacquet M; Propst M; Liu W; Corash L; Sundin D; Defoin L; Messe N; Osselaer JC Transfusion; 2010 Jun; 50(6):1210-9. PubMed ID: 20113450 [TBL] [Abstract][Full Text] [Related]
17. Transfusion therapy and acute lung injury. Sokolovic M; Pastores SM Expert Rev Respir Med; 2010 Jun; 4(3):387-93. PubMed ID: 20524921 [TBL] [Abstract][Full Text] [Related]
18. The Incidence Rate of Acute Transfusion Reactions in Thalassemia Patients Referred to the Shiraz Thalassemia Centre, Shiraz, Iran, Before and After the Establishment of the Hemovigilance System. Kasraian L; Karimi MH Hemoglobin; 2015; 39(4):274-80. PubMed ID: 26036919 [TBL] [Abstract][Full Text] [Related]
19. Use of hemovigilance data to evaluate the effectiveness of diversion and bacterial detection. Robillard P; Delage G; Itaj NK; Goldman M Transfusion; 2011 Jul; 51(7):1405-11. PubMed ID: 21214581 [TBL] [Abstract][Full Text] [Related]